IL98233A0 - Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertusis antigens - Google Patents

Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertusis antigens

Info

Publication number
IL98233A0
IL98233A0 IL98233A IL9823391A IL98233A0 IL 98233 A0 IL98233 A0 IL 98233A0 IL 98233 A IL98233 A IL 98233A IL 9823391 A IL9823391 A IL 9823391A IL 98233 A0 IL98233 A0 IL 98233A0
Authority
IL
Israel
Prior art keywords
pertusis
antigens
combination
bordetella pertussis
vaccines against
Prior art date
Application number
IL98233A
Other languages
English (en)
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24192174&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL98233(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of IL98233A0 publication Critical patent/IL98233A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL98233A 1990-07-11 1991-05-23 Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertusis antigens IL98233A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54923690A 1990-07-11 1990-07-11

Publications (1)

Publication Number Publication Date
IL98233A0 true IL98233A0 (en) 1992-06-21

Family

ID=24192174

Family Applications (1)

Application Number Title Priority Date Filing Date
IL98233A IL98233A0 (en) 1990-07-11 1991-05-23 Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertusis antigens

Country Status (10)

Country Link
US (4) US5885587A (de)
EP (1) EP0484621A3 (de)
JP (1) JPH04230328A (de)
KR (1) KR920002790A (de)
AU (1) AU8033591A (de)
CA (1) CA2046543A1 (de)
FI (1) FI913350A7 (de)
IL (1) IL98233A0 (de)
NO (1) NO912713L (de)
PT (1) PT98257A (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8412207D0 (en) 1984-05-12 1984-06-20 Wellcome Found Antigenic preparations
GB8910570D0 (en) 1989-05-08 1989-06-21 Wellcome Found Acellular vaccine
US5156958A (en) * 1990-09-21 1992-10-20 American Cyanamid Company Gene encoding a 30 kilodalton outer membrane protein of bordetella pertussis and method of recombinant production of said protein
US6444211B2 (en) * 1991-04-03 2002-09-03 Connaught Laboratories, Inc. Purification of a pertussis outer membrane protein
GB9209118D0 (en) * 1992-04-28 1992-06-10 Sb 120 Amsterdam Bv Vaccine compositions
DE69434000T3 (de) 1993-10-05 2008-11-06 UCB Pharma Ltd., Slough Impfstoffzusammensetzungen
KR100266556B1 (ko) * 1994-04-28 2000-09-15 다께다구니오 백일해균의 방어성분의 분리방법
ATE496634T1 (de) 1995-05-04 2011-02-15 Sanofi Pasteur Ltd Azelluläre pertussis-impfstoffe und verfahren zu deren herstellung
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US20020054884A1 (en) 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
GB9611501D0 (en) * 1996-06-03 1996-08-07 Smithkline Beecham Biolog Vaccine compositions
DE69736709T2 (de) * 1996-07-02 2007-10-04 Sanofi Pasteur Ltd., Toronto Vielwertige dtp-polio-impfstoffe
US20010014331A1 (en) * 1996-11-07 2001-08-16 Smithkline Beecham Biologicals S.A. Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
US7087236B1 (en) * 1998-09-01 2006-08-08 Merrion Research I Limited Method for inducing a cell-mediated immune response and improved parenteral vaccine formulations thereof
US7172762B1 (en) * 1999-01-29 2007-02-06 Pfizer Inc. Erysipelothrix rhusiopathiae antigens and vaccine compositions
US20020009466A1 (en) * 1999-08-31 2002-01-24 David J. Brayden Oral vaccine compositions
JP2001085516A (ja) * 1999-09-10 2001-03-30 Oki Electric Ind Co Ltd 半導体装置の製造方法
GB9924351D0 (en) 1999-10-14 1999-12-15 Brennan Frank Immunomodulation methods and compositions
FR2809960B1 (fr) * 2000-06-07 2004-04-23 Pasteur Institut Composition adjuvante de la reponse immunitaire comprenant la proteine fha ou un fragment de la proteine fha sous forme libre, et composition immunogene ou vaccinale contenant une telle composition adjuvante
DK2116257T3 (da) * 2000-08-09 2013-02-04 Alk Abello As Parenterale vaccineformuleringer og anvendelser deraf
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
AU2003221896A1 (en) * 2002-04-09 2003-10-27 Neville Alleyne Bone fixation apparatus
EP1667712B1 (de) * 2003-10-02 2010-07-21 GlaxoSmithKline Biologicals S.A. B. pertussis antigene und ihre verwendung bei der vakzinierung
US7578803B2 (en) * 2004-03-18 2009-08-25 C. R. Bard, Inc. Multifunction adaptor for an open-ended catheter
US20060115499A1 (en) * 2004-09-27 2006-06-01 Alk-Abello A/S Liquid allergy vaccine formulation for oromucosal administration
BRPI0519923A8 (pt) * 2004-12-17 2018-01-23 De Staat Der Nederlanden Vertegenwoordigd Door De Mini Van Vws polipeptídeo, seqüência de dna, vetor de dna, anticorpo, bactéria, método para produzir lps parcialmente 3-0-desacilado, composição, usos da bactéria, e de lps de bordetella isolado compreendendo lps pelo menos parcialmente 3-0-desacilado, vacina, e, método in vitro para a desacilação de lps gram-negativo ou de composições compreendendo lps gram-negativo, e, para induzir uma resposta imune contra bordetella.
WO2007111326A1 (ja) * 2006-03-27 2007-10-04 The Kitasato Institute 長期保存においても毒性復帰がおこらない特徴を持つ全菌体細菌ワクチンならびにその用途
JP5814507B2 (ja) 2006-09-07 2015-11-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
CN101784655A (zh) * 2007-04-27 2010-07-21 菲尼克斯股份有限公司 可溶性重组二十面体病毒样颗粒的改良生成和体内装配
KR100906369B1 (ko) 2009-01-14 2009-07-06 김세영 수유 쿠션
WO2014135651A1 (en) 2013-03-08 2014-09-12 Crucell Holland B.V. Acellular pertussis vaccine
WO2017197034A1 (en) 2016-05-10 2017-11-16 Najit Technologies, Inc. Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
US20230090238A1 (en) * 2021-09-17 2023-03-23 Advanced Rx Compositions, methods, systems and kits for the treatment of nosebleeds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338299A (en) * 1980-11-17 1982-07-06 Dso "Pharmachim" Vaccine against pertussis
CA1209036A (en) * 1982-08-20 1986-08-05 Joseph S.C. Kuo Combined haemophilus influenzae and diphtheria, pertussis, tetanus vaccine
GB8412207D0 (en) * 1984-05-12 1984-06-20 Wellcome Found Antigenic preparations
FR2590483B1 (fr) * 1985-11-22 1988-12-09 Pasteur Institut Antigenes purifies ayant des proprietes vaccinantes contre b. pertussis, moyens notamment adns recombinants pour les produire et compositions de vaccins les contenant
GB8601279D0 (en) * 1986-01-20 1986-02-26 Public Health Lab Service Purification of pertussis antigens
FR2597344B1 (fr) * 1986-04-16 1989-06-23 Merieux Inst Perfectionnement au procede de purification d'antigenes proteiques de bacteries appartenant au genre bordetella, en vue de l'obtention d'un vaccin acellulaire.
GB8910570D0 (en) * 1989-05-08 1989-06-21 Wellcome Found Acellular vaccine
US5276142A (en) * 1989-12-11 1994-01-04 American Cyanamid Company Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis
US5578308A (en) * 1990-02-12 1996-11-26 Capiau; Carine Glutaraldehyde and formalin detoxified bordetella toxin vaccine
IT1248735B (it) * 1990-06-21 1995-01-26 Sclavo Spa Vaccini acellulari contro la pertosse

Also Published As

Publication number Publication date
FI913350L (fi) 1992-01-12
FI913350A0 (fi) 1991-07-10
EP0484621A2 (de) 1992-05-13
CA2046543A1 (en) 1992-01-12
FI913350A7 (fi) 1992-01-12
US5885586A (en) 1999-03-23
NO912713D0 (no) 1991-07-10
KR920002790A (ko) 1992-02-28
AU8033591A (en) 1992-01-16
JPH04230328A (ja) 1992-08-19
NO912713L (no) 1992-01-13
PT98257A (pt) 1992-04-30
EP0484621A3 (en) 1992-08-26
US5895655A (en) 1999-04-20
US5885587A (en) 1999-03-23
US5897867A (en) 1999-04-27

Similar Documents

Publication Publication Date Title
IL98233A0 (en) Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertusis antigens
US5182109C1 (en) Vaccine preparation comprising a bacterial toxin adjuvant
GB9412682D0 (en) Miniature silicon accelerometer and method
CY2614B2 (en) Combined vaccines comprising Hepatitis B surface and other antigens
SG49909A1 (en) Vaccine composition containing adjuvants
GB9001766D0 (en) Vaccines
EP0462534A3 (en) Acellular anti-pertussis vaccines
EP0474646A4 (en) Bordetella vaccines
PL308555A1 (en) Conjugate vaccine against streptococcus of b group
AU5768986A (en) Filamentous haemagglutinin and pertussis antigen vaccines from bordetella
EP0463157A4 (en) Lfa-3 as a vaccine adjuvant
IL90994A0 (en) Bordetella pertussis vaccine
GB9017370D0 (en) Tuberculosis vaccine
EP0447322A3 (en) A process for preparing a purified treponemal antigen and use thereof
IE892369L (en) Bordetella pertussis vaccine
NZ224862A (en) Taenia ovis antigens and vaccines
GB2091551B (en) Vaccine against pertussis
GB9416333D0 (en) Miniature silicon accelerometer and method
GB9021004D0 (en) Acellular vaccines
GB9126395D0 (en) A method of preparing a vaccine against paramixo virus infections
GR3022679T3 (en) Vaccine adjuvant comprising a tetra-polyol
GB8818340D0 (en) Antigenic determinants
GB8817557D0 (en) Antigenic determinants
IL95006A0 (en) Oral vaccines
GB9020584D0 (en) Vaccine